Publication Name	World Journal of Hepatology
Manuscript ID	121656
Country	United States

Category	Oncology
Manuscript Type	Meta-Analysis
Article Title	Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis
Manuscript Source	Unsolicited Manuscript
All Author List	Ronald Blanco Montecino, Nehemias Guevara Rodriguez, Noemy Coreas, Daniel Mendoza-Quispe, Yassine Kilani, Syeda Ashna Fatima Kamal, Kamran Qureshi and John M Richart
Funding Agency and Grant Number
Corresponding Author	Ronald Blanco Montecino, MD, Department of Internal Medicine, Saint Barnabas Hospital, CUNY School of Medicine, 4422 Third Avenue, Bronx, NY 10457, United States. ronaldmau94@gmail.com
Key Words	Hepatocellular carcinoma; Tyrosine kinase inhibitors; Atezolizumab; Bevacizumab; Second-line therapy; Disease progression; Survival outcomes; Adverse events; Meta-analysis
Core Tip	Atezolizumab plus bevacizumab represents the standard first-line therapy for advanced hepatocellular carcinoma; however, treatment options after disease progression remain poorly defined. Tyrosine kinase inhibitors, established prior to the immunotherapy era, are frequently used in this setting, although their effectiveness after prior immunotherapy exposure is not well characterized. Therefore, a comprehensive evaluation of their role is needed. Our meta-analysis assessed the efficacy and safety of tyrosine kinase inhibitors after progression on atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.
Citation	Blanco Montecino R, Guevara Rodriguez N, Coreas N, Mendoza-Quispe D, Kilani Y, Kamal SA, Qureshi K, Richart JM. Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2026; In press

Received	2026-03-30 00:55
Peer-Review Started	2026-03-31 07:04
First Decision by Editorial Office Director	2026-04-15 07:58
Return for Revision	2026-04-15 07:58
Revised	2026-05-03 03:40
Publication Fee Transferred
Second Decision by Editor	2026-05-27 02:43
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-05-27 06:19
Articles in Press	2026-05-27 06:19
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com